KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Gsk (GSK) Operating Expenses (2016 - 2026)

Gsk has reported Operating Expenses over the past 18 years, most recently at -$5.1 billion for Q1 2026.

  • For Q1 2026, Operating Expenses fell 15.5% year-over-year to -$5.1 billion; the TTM value through Mar 2026 reached -$38.1 billion, up 1.35%, while the annual FY2025 figure was $22.1 billion, 1.14% down from the prior year.
  • Operating Expenses for Q1 2026 was -$5.1 billion at Gsk, up from -$22.1 billion in the prior quarter.
  • Over five years, Operating Expenses peaked at -$3.9 billion in Q1 2022 and troughed at -$22.4 billion in Q4 2024.
  • A 5-year average of -$8.4 billion and a median of -$5.0 billion in 2024 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: tumbled 39.35% in 2024 and later increased 22.43% in 2025.
  • Year by year, Operating Expenses stood at -$16.3 billion in 2022, then dropped by 19.16% to -$19.4 billion in 2023, then dropped by 15.39% to -$22.4 billion in 2024, then rose by 1.14% to -$22.1 billion in 2025, then soared by 76.75% to -$5.1 billion in 2026.
  • Business Quant data shows Operating Expenses for GSK at -$5.1 billion in Q1 2026, -$22.1 billion in Q4 2025, and -$5.3 billion in Q3 2025.